Bewertung der Wirksamkeit von Neothel FT bei der Behandlung chronischer offener Wunden
Bewertung der Wirksamkeit von Neothel FT bei der Heilung chronischer offener Wunden: Eine randomisierte kontrollierte multizentrische Studie
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care (SOC) alone, or SOC plus NeoThelium FT.
The study includes a crossover component for subjects in the SOC arm. At treatment visit 13 (approximately 84 days post-randomization), SOC arm subjects not having achieved complete wound closure, and still meeting the inclusion/exclusion criteria, are eligible to cross over to the IP arm (SOC plus NeoThelium FT). Crossover subjects will begin IP arm treatment with weekly NeoThelium FT applications for up to 12 treatment visits. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions. All subjects will complete two-week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks. Secondary endpoints consist of wound percentage area reduction rates and pain assessment.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Angelina Ferguson, DNP
- Telefonnummer: (985) 629-4013
- E-Mail: info@sygnola.com
Studieren Sie die Kontaktsicherung
- Name: Sarah Moore, MBE
- Telefonnummer: (985) 629-4013
- E-Mail: info@sygnola.com
Studienorte
-
-
Louisiana
-
Denham Springs, Louisiana, Vereinigte Staaten, 70726
- Rekrutierung
- MedCentris of Denham Springs
-
Hauptermittler:
- Monique Consoer, NP
-
Kontakt:
- Tabatha Yent
- E-Mail: tabatha.yent@medcentris.com
-
Hammond, Louisiana, Vereinigte Staaten, 70403
- Rekrutierung
- MedCentris of Hammond
-
Hauptermittler:
- Chris Keaton, NP
-
Kontakt:
- Chelsea Smith, RN
- E-Mail: Chelsea.smith@medcentris.com
-
Kontakt:
- Melanie Knox, LPN
- E-Mail: Melanie.knox@medcentris.com
-
Lafayette, Louisiana, Vereinigte Staaten, 70507
- Abgeschlossen
- MedCentris of Carencro
-
Leesville, Louisiana, Vereinigte Staaten, 71146
- Rekrutierung
- MedCentris of Leesville
-
Hauptermittler:
- Stefanie Corley, FNP
-
Kontakt:
- Brandi Shuff
- E-Mail: Brandi.shuff@medcentris.com
-
Many, Louisiana, Vereinigte Staaten, 71449
- Rekrutierung
- MedCentris of Many
-
Hauptermittler:
- Stefanie Corley, FNP
-
Kontakt:
- Brandi Shuff
- E-Mail: Brandi.Shuff@medcentris.com
-
Marksville, Louisiana, Vereinigte Staaten, 71351
- Rekrutierung
- MedCentris of Marksville
-
Hauptermittler:
- Averie Rachal, FNP
-
Kontakt:
- Laura Whittington
- E-Mail: Laura.whittington@medcentris.com
-
Metairie, Louisiana, Vereinigte Staaten, 70001
- Rekrutierung
- MedCentris of Metairie
-
Kontakt:
- Ninya Powell
- E-Mail: ninya.powell@medcentris.com
-
Hauptermittler:
- Sarah Logrande, NP
-
Minden, Louisiana, Vereinigte Staaten, 71055
- Rekrutierung
- MedCentris of Minden
-
Hauptermittler:
- Taheera Forbes, NP
-
Kontakt:
- Brianna Thompas
- E-Mail: brianna.thompson@medcentris.com
-
Monroe, Louisiana, Vereinigte Staaten, 71201
- Noch keine Rekrutierung
- MedCentris of Monroe
-
Hauptermittler:
- Libbi Trawick, NP
-
Kontakt:
- Tiffany Dew
- E-Mail: Tiffany.dew@medcentris.com
-
Slidell, Louisiana, Vereinigte Staaten, 70458
- Rekrutierung
- MedCentris of Slidell
-
Hauptermittler:
- Katie Schloegel, FNP
-
Kontakt:
- Donyille Singletary, RN
- Telefonnummer: 985-602-1215
- E-Mail: Donyille.singletary@medcentris.com
-
-
Mississippi
-
D'Iberville, Mississippi, Vereinigte Staaten, 39540
- Abgeschlossen
- MedCentris of D'iberville
-
McComb, Mississippi, Vereinigte Staaten, 39648
- Abgeschlossen
- MedCentris of McComb
-
Natchez, Mississippi, Vereinigte Staaten, 39120
- Abgeschlossen
- MedCentris of Natchez
-
Southaven, Mississippi, Vereinigte Staaten, 38671
- Rekrutierung
- MedCentris of Southaven
-
Hauptermittler:
- Carlene McAllister, NP
-
Kontakt:
- De'Nyia Woods
- E-Mail: denyia.woods@medcentris.com
-
-
New York
-
Brooklyn, New York, Vereinigte Staaten, 11234
- Rekrutierung
- Northeast Podiatry Consultant
-
Kontakt:
- Thomas Hayes
- E-Mail: thomas@simonfootandankle.com
-
Hauptermittler:
- David Simon, DPM, FACFAS
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or Female, 18 years of age or older
- Subject has a medical diagnosis of "other" Open wound
- Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
- Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
- Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
- Subject has an Open wound without infection or clinically visible exposed bone
- Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
- Index ulcer has a maximum depth of 1cm at screening visit 1
- The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
- Adequate circulation of wounds located below the knee demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
- Index ulcer is free of infection prior to randomization and during screening phase.
- Index ulcer is free of necrotic debris prior to NeoThelium FT application
- Female subjects of childbearing potential having a negative pregnancy test prior to randomization
- Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
- Subject is able and willing to follow the protocol requirements
- Subject had signed informed consent
- If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm
Exclusion Criteria:
- Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
- Subject has a known life expectancy of <1 year
- Subject is unable to comply with protocol treatment
- Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
- Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
- Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
- Known contraindications to tissue-engineered allograft
- Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
- Subject is pregnant or breastfeeding
- Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
- Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
- Open wound with active infection
- Wound depth with visible exposed bone
- HBOT within 14 days prior to randomization
- Revascularization surgery on the index wound leg within 30 days of screening phase
- Index wound suspicious of neoplasm in the opinion of the principal investigator
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: No Intervention: Standard of Care
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
|
Experimental: Intervention: NeoThelium FT & Standard of Care
Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading |
NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Complete Wound Closure
Zeitfenster: 1-12 weeks
|
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure. |
1-12 weeks
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage Wound Area Change
Zeitfenster: 1-12 weeks
|
The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination. |
1-12 weeks
|
|
Pain Assessment
Zeitfenster: Day 0, Day 14, Day 35, Day 56, Day 84
|
Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points |
Day 0, Day 14, Day 35, Day 56, Day 84
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Follow-Up Closure
Zeitfenster: 2 weeks
|
Number of wounds remaining closed during the 2-week follow-up |
2 weeks
|
|
Adverse Events and Serious Adverse Events
Zeitfenster: Day -14 through 91 days
|
The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported. |
Day -14 through 91 days
|
|
Time to Closure
Zeitfenster: 1-12 weeks
|
Average number of grafts and/or weeks used to achieve wound closure |
1-12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Studienleiter: Angelina Ferguson, DNP, SygNola, LLC
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- HEAL
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .